Business
‘Groundbreaking approach’: Imugene deal looks to smash solid tumours – Sydney Morning Herald
The $1.5 billion biotech will work with Nasdaq-listed firm Celularity in hopes of cracking the mystery of how to target tough…
Imugene, the cancer treatment maker chaired by biotech veteran Paul Hopper, is banking on a partnership with Nasdaq-listed biotech Celularity to unlock a revolutionary treatment that will obliterate solid tumours.
The Sydney-based company, which has seen…
Continue Reading
-
Noosa News24 hours agoBali traveller sparks urgent measles alert across Queensland
-
Noosa News24 hours agoQueensland man sentenced to four years imprisonment after string of terror offences
-
Business24 hours agoThe best ASX ETFs for compounding wealth until 2040
-
Noosa News22 hours agoMeasles alert issued south of Brisbane after traveller tests positive